Managing infections in pregnancy

Current Opinion in Infectious Diseases

Volumn 27, Issue 3, 2014, Pages 251-257

  Ville, Yves ^a,b   Leruez Ville, Marianne ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

congenital infection; cytomegalovirus; influenza; serology; toxoplasmosis; vaccine

Indexed keywords

CYTOMEGALOVIRUS VACCINE; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN G; PYRIMETHAMINE; SPIRAMYCIN; SULFADIAZINE; VALGANCICLOVIR; ANTIPROTOZOAL AGENT; ANTIVIRUS AGENT;

AMNIOCENTESIS; ANTIVIRAL THERAPY; CONGENITAL INFECTION; CONGENITAL TOXOPLASMOSIS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; EUROPE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HEALTH CARE POLICY; HUMAN; IMMUNIZATION; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; META ANALYSIS (TOPIC); NEWBORN CARE; NONHUMAN; PERINATAL CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PREDICTION; PREGNANCY; PRENATAL CARE; PRENATAL DIAGNOSIS; PRIMARY INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SEROCONVERSION; SEROPREVALENCE; SYSTEMATIC REVIEW (TOPIC); VERTICAL TRANSMISSION; ADULT; AMNION FLUID; ANALOGS AND DERIVATIVES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; NEWBORN; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; PROGNOSIS; TOXOPLASMOSIS, CONGENITAL; TRANSMISSION; VIROLOGY;

ADULT; AMNIOTIC FLUID; ANTIPROTOZOAL AGENTS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL DIAGNOSIS; PROGNOSIS; TOXOPLASMOSIS, CONGENITAL;

EID: 84900455963     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000066     Document Type: Review

References (31)

1. Townsend CL, Forsgren M, Ahlfors K, et al. Long-term outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom. Clin Infect Dis 2013; 56:1232-1239.
2. De Vries JJC, van Zwet EW, Dekker FW, et al. The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a population-based prediction model. Rev Med Virol 2013; 23:241-249.
3. Gollub EL, Leroy V, Gilbert R, et al., European Toxoprevention Study Group (EUROTOXO). Effectiveness of health education on Toxoplasma-related knowledge, behaviour, and risk of seroconversion in pregnancy. Eur J Obstet Gynecol Reprod Biol 2008; 136:137-145.
4. Leruez-Ville M, Sellier Y, Salomon LJ, et al. Prediction of fetal infection in cases with cytomegalovirus immunoglobulin M in the first trimester of pregnancy: a retrospective cohort. Clin Infect Dis 2013; 56:1428-1435.
5. Benoist G, Leruez-Ville M, Magny JF, et al. Management of pregnancies with confirmed cytomegalovirus fetal infection. Fetal Diagn Ther 2013;33:203-214.
6. Picone O, Vauloup-Fellous C, Cordier AG, et al. A series of 238 cyto-megalovirus primary infections during pregnancy: description and outcome. Prenat Diagn 2013; 33:751-758.
7. Nigro G, Adler SP, La Torre R, Best AM, Congenital Cytomegalovirus Collaborating Group. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005; 353:1350-1362.
8. Nigro G, Adler SP, Parruti G, et al. Immunoglobulin therapy of fetal cyto-megalovirus infection occurring in the first half of pregnancy: a case-control study of the outcome in children. J Infect Dis 2012; 205:215-227.
9. Visentin S, Manara R, Milanese L, et al. Early primary cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. Clin Infect Dis 2012; 55:497-503.
10. Revello MG. Results of the CHIP study. Oral communication presented at the Congenital CMV Conference, San Francisco, CA, 29October to 2 November 2012.
11. Hodson EM, Craig JC, Strippoli GFM, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008; CD003774.
12. Turner KM, Lee HC, Boppana SB, et al. Incidence and impact of CMV infection in very low birth weight infants. Pediatrics 2014; 133: e609-e615.
13. Sharland M, Luck S, Griffiths P, Cotton M. Antiviral therapy of CMV disease in children. Adv Exp Med Biol 2011; 697:243-260.
14. Gracia Revello M, Percivalle E, Baldanti F, et al. Prenatal treatment of congenital human cytomegalovirus infection by fetal intravascular administration of ganciclovir. Clin Diagn Virol 1993; 1:61-67.
15. Jacquemard F, Yamamoto M, Costa J-M, et al. Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. BJOG Int J Obstet Gynaecol 2007; 114:1113-1121.
16. Teissier N, Fallet-Bianco C, Delezoide A-L, et al. Cytomegalovirus- induced brain malformationsinfetuses. JNeuropathol Exp Neurol 2014; 73:143-158.
17. Krause PR, Bialek SR, Boppana SB, et al. Priorities for CMV vaccine development. Vaccine 2013; 32:4-10.
18. Griffiths P, Plotkin S, Mocarski E, et al. Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine 2013; 31 (Suppl 2):B197-B203.
19. Dempsey AF, Pangborn HM, Prosser LA. Cost-effectiveness of routine vaccination of adolescent females against cytomegalovirus. Vaccine 2012; 30:4060-4066.
20. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cyto-megalovirus infection. N Engl J Med 2009; 360:1191-1199.
21. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12:290-299.
22. Sö derberg-Nauclér C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med 2006; 259: 219-246.
23. Schleiss MR. Developing a vaccine against congenital cytomegalovirus (CMV) infection: what have we learned from animal models? Where should we go next? Future Virol 2013; 8:1161-1182.
24. Wallon M, Peyron F, Cornu C, et al. Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years. Clin Infect Dis 2013; 56:1223-1231.
25. Nogareda F, LE Strat Y, Villena I, et al. Incidence and prevalence of Toxoplasma gondii infection in women in France, 1980-2020: model-based estimation. Epidemiol Infect 2013; 14:1-10.
26. Bénard A, Petersen E, Salamon R, et al. Survey of European programmes for the epidemiological surveillance of congenital toxoplasmosis. Euro Surveill 2008; 13:pii: 18834.
27. Flatt A, Shetty N. Seroprevalence and risk factors for toxoplasmosis among antenatal women in London: a re-examination of risk in an ethnically diverse population. Eur J Public Health 2013; 23:648-652.
28. Di Mario S, Basevi V, Gagliotti C, et al. Prenatal education for congenital toxoplasmosis. Cochrane Database Syst Rev 2013; 2:CD006171.
29. SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group. Thiébaut R, Leproust S, Chêne G, Gilbert R. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet 2007; 369:115-122.
30. Kravetz J. Congenital toxoplasmosis. Clin Evid (Online) 2013; 2008: 0906.
31. Luteijn JM, Brown MJ, Dolk H. Influenza and congenital anomalies: a systematic review and meta-analysis. Hum Reprod Oxf Engl 2014; 29:809-823.